<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114165">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01721967</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00039302</org_study_id>
    <secondary_id>3938381</secondary_id>
    <nct_id>NCT01721967</nct_id>
  </id_info>
  <brief_title>Ranolazine for the Treatment of Chest Pain in HCM Patients</brief_title>
  <acronym>RHYME</acronym>
  <official_title>Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of RHYME is to evaluate the safety and efficacy of ranolazine in Hypertrophic
      Cardiomypathy patients with chest pain or dyspnea despite treatment with standard medical
      therapy.  This is a small, pilot, open-label (non-randomized) study of an approved drug for
      the treatment of angina in a novel patient population (adult patient population with
      hypertrophic cardiomyopathy).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Chest Pain</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following 2 months of therapy with ranolazine, symptomatic patients with Hypertrophic Cardiomyopathy will demonstrate signals of improvement on testing including angina frequency evaluation (number of episodes of angina per week).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine, 500 mg for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Left Ventricle wall thickness &gt;/= 15mm in the absence of other condition causing
             hypertrophy

          -  Baseline Angina/Shortness of Breath Frequency of &gt; 2 episodes per week

          -  Willing to provide informed consent

        Exclusion Criteria:

          -  Severe stenotic valvular disease

          -  Severe valvular regurgitation except mitral regurgitation due to systolic anterior
             motion

          -  Significant (&gt;60% stenosis) coronary artery disease

          -  Acute coronary syndrome within 30 days

          -  Severe heart failure defined as LV systolic dysfunction with Ejection Fraction &lt;40%
             or NYHA class 4 symptoms

          -  Severe renal impairment (glomerular filtration rate, &lt;30 mL/min/1.73 m2)

          -  Moderate-severe hepatic impairment (Child-Pugh classes B and C)

          -  Hospitalization for cardiac reason within 3 months of enrollment

          -  Anticipated changes to treatment of HCM within study period, including medications,
             device implantation, or septal reduction therapies

          -  Concomitant use of ketoconazole, macrolide antibiotics, and HIV protease inhibitors

          -  Active myocarditis, pericarditis, or restrictive cardiomyopathy

          -  Non-cardiac terminal illness with expected survival less than 6 months

          -  Women who are of childbearing potential

          -  Inability to perform or adhere to study protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>November 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Andrew Wang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>chest pain</keyword>
  <keyword>dyspnea</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
